2352-36-5

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 100-01-6 4-nitro-aniline 

Downstream Products

• 155994-11-9 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-m-tolyl-thiourea 
• 155994-12-0 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-p-tolyl-thiourea 
• 155994-10-8 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-o-tolyl-thiourea 
• 155994-14-2 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(3-chloro-phenyl)-thiourea 
• 155994-17-5 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(3-nitro-phenyl)-thiourea 
• 155994-18-6 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(4-nitro-phenyl)-thiourea 
• 155994-16-4 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(2-nitro-phenyl)-thiourea 
• 155994-13-1 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(2-chloro-phenyl)-thiourea 
• 155994-09-5 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-phenyl-thiourea 
• 155994-15-3 1-[4-Chloro-6-(4-nitro-phenylamino)-[1,3,5]triazin-2-yl]-3-(4-chloro-phenyl)-thiourea 
• 1084910-37-1 C₂₅H₂₁N₇O₂S₄ 
• 6803-95-8 6-chloro-N²-(4-methoxy-phenyl)-N⁴-(4-nitro-phenyl)-[1,3,5]triazine-2,4-diamine 
• 39003-06-0 6-chloro-N-(4-nitro-phenyl)-[1,3,5]triazine-2,4-diamine 

Relevant academic research and scientific papers

Syntheses of 2,4,6-trisubstituted triazines as antimalarial agents

A series of 2,4,6-trisubstituted-1,3,5-triazines (2a-s) were synthesized and evaluated for their in vitro antimalarial activity against P. falciparum. Out of the 19 compounds synthesized eight compounds showed MIC in the range of 1-2 μg/mL. These compounds are in vitro several times more active than cycloguanil.

Design and development of novel thiazolidin-4-one-1,3,5-triazine derivatives as neuro-protective agent against cerebral ischemia–reperfusion injury in mice via attenuation of NF-?B

The present study enumerates the discovery and development of novel thiazolidin-4-one-1,3,5-triazine as neuro-protective agent against cerebral ischemia–reperfusion injury in mice. These compounds showed significant inhibition of NF-?B transcriptional activity in LPS-stimulated RAW264.7 cells, displaying compound 8k as most potent inhibitor among the tested derivative. The compound 8k was further studied in in vivo middle cerebral artery occlusion (MCAO) mice model for neuro-protective action. Results suggest that compound 8k causes attenuation of inflammation (TNF-α, IL-β, and IL-6), oxidative stress (SOD, GSH, and MDA), and apoptosis (Bcl-2, Bax, and cleaved caspase-3) in MCAO mice in concentration-dependent manner. Collectively, our results documented that compound 8k pre-treatment protects cerebral I/R. This novel lead scaffold may be helpful for investigation of new neuro-protective agent by inactivation of NF-?B.

Selective inhibition of human cathepsin S by 2,4,6-trisubstituted 1,3,5-triazine analogs

We report herein the synthesis and biological evaluation of a new series of 2,4,6-trisubstituted 1,3,5-triazines as reversible inhibitors of human cysteine cathepsins. The desired products bearing morpholine and N-Boc piperidine, respectively, were obtained in three to four steps from commercially available trichlorotriazine. Seventeen hitherto unknown compounds were evaluated in vitro against various cathepsins for their inhibitory properties. Among them, compound 7c (4-(morpholin-4-yl)-6-[4-(trifluoromethoxy)anilino]-1,3,5-triazine-2-carbonitrile) was identified as the most potent and selective inhibitor of cathepsin S (Ki = 2 ± 0.3 nM). Also 7c impaired the autocatalytic maturation of procathepsin S. Molecular docking studies support that 7c bound within the active site of cathepsin S, by interacting with Gly23, Cys25 and Trp26 (S1 subsite), with Asn67, Gly69 and Phe70 (S2 subsite) and with Gln19 (S1′ pocket).

Synthesis of series of triazine derivatives and their evaluation against root knot nematode meloidogyne incognita

Nine triazine derivatives were synthesized by reacting triazine with different aromatic amines. The synthesized derivatives were characterized by IR, NMR spectral studies and micro analytical data. The resulted compounds had also been evaluated for their in vitro antinemic studies against root knot nematode, Meloidogyne incognita. All compounds showed considerable nematicidal activity as compared to the control when screened for their hatching inhibition and mortality potential.

Docking, synthesis and antimalarial activity of novel 4-anilinoquinoline derivatives

A series of 4-anilinoquinoline triazine derivatives were designed, synthesized and screened for in vivo antimalarial activity against a chloroquine-sensitive strain of Plasmodium berghei. The compounds were further subjected to in vitro antimalarial activity against chloroquine-resistant W2 strain of Plasmodium falciparum and β-haematin inhibition studies. All the compounds exhibited in vivo antimalarial activity better than that shown by the standard drug, chloroquine. Twelve out of fifteen compounds showed better inhibition than that of chloroquine against chloroquine-resistant W2 strain of Plasmodium falciparum. Ten compounds showed β-haematin inhibition, better than that of chloroquine, with IC50 values in the range of 18–25?μM. One compound, 3k, was found to be better than artemisinin against W2 strain of Plasmodium falciparum and also displayed the best β-haematin inhibitory activity, thereby becoming eligible to be explored as a potential lead for antimalarial chemotherapy.

Synthesis, docking, in vitro and in vivo antimalarial activity of hybrid 4-aminoquinoline-1,3,5-triazine derivatives against wild and mutant malaria parasites

A new series of hybrid 4-aminoquinoline-1,3,5-triazine derivatives was synthesized by a four-step reaction. Target compounds were screened for in vitro antimalarial activity against chloroquine-sensitive (3D-7) and chloroquine-resistant (RKL-2) strains of Plasmodium falciparum. Compounds exhibited, by and large, good antimalarial activity against the resistant strain, while two of them, that is 8g and 8a, displayed higher activity against both the strains of P. falciparum. Additionally, docking study was performed on both wild (1J3I.pdb) and quadruple mutant (N51I, C59R, S108 N, I164L, 3QG2.pdb) type pf-DHFR-TS to highlight the structural features of hybrid molecules. A series of hybrid 4-aminoquinoline was synthesized and evaluated for antimalarial activity against chloroquine-sensitive (3D-7) and chloroquine-resistant (RKL-2) strains of P. falciparum.

Development of 4-aminoquinoline-1,3,5-triazine conjugates as potent antibacterial agent through facile synthetic route

A series of novel hybrid 4-aminoquinoline-1,3,5-triazine derivatives were developed and subsequently tested against representative Gram-positive and Gram-negative microorganisms for determination of their antibacterial activity. Screening results indicate that, title molecule exhibit moderate to potent activity in comparison to standard. These hybrid derivatives were synthesized through a facile synthetic routes and structure of reaction intermediates as well as target molecules were recognised with the aid of various spectroscopic techniques viz., FTIR, NMR, mass and elemental analysis.

Synthesis and antibacterial activity of some novel 4-benzyl-piperazinyl-s- triazine derivatives

Considerable interest has been attracted in s-triazine scaffold and its derivatives because of their large variety of pharmacological activities. In this project, a series of 4-benzyl-piperazinyl-s-triazine derivatives 5a to 5j were synthesized by three steps substitution reaction of cyanuric chloride with various nucleophilic compounds in presence of a base. Molecular structures of the synthesized compounds were elucidated by FTIR, 1H NMR, 13C NMR, MS spectral data and elemental analyses. The in vivo antibacterial activity was evaluated by broth dilution method against representative four Gram-positive and four Gram-negative bacterial strains. Many compounds have displayed comparable better antibacterial activity against Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermis and Pseudomonas aeruginosa with reference to streptomycin.

Elaborate ligand-based modeling and subsequent synthetic exploration unveil new nanomolar Ca2+/calmodulin-dependent protein kinase II inhibitory leads

Ca2+/calmodulin-dependent protein kinase II (CaMKII) has been recently implicated in cardiovascular diseases and hypertension prompting several attempts to discover and optimize new CaMKIIδ inhibitors. Towards this end we explored the pharmacophoric space of 88 CaMKIIδ inhibitors using nine diverse sets of inhibitors to identify high quality pharmacophores. Subsequently, genetic algorithm and multiple linear regression analysis were employed to select an optimal combination of pharmacophoric models and 2D physicochemical descriptors capable of accessing self-consistent quantitative structure-activity relationship (QSAR) of optimal predictive potential (r722=0.70, F = 18.19, rLOO2=0.71, rPRESS2 against 16 external test inhibitors = 0.60). Three orthogonal pharmacophores emerged in the QSAR equation suggesting the existence of at least three binding modes accessible to ligands within CaMKIIδ binding pocket. Receiver operating characteristic (ROC) curves analysis established the validity of QSAR-selected pharmacophores. We employed the pharmacophoric models and associated QSAR equation to screen the national cancer institute (NCI) list of compounds. In silico screening identified nanomolar and low micromolar inhibitors. The most potent hits exhibited IC 50 values of 20 and 82 nM. The best pharmacophoric model (Hypo8/31) was employed to guide the synthesis of novel triazine-based CaMKIIδ inhibitors, of which the most potent illustrated an IC50 value of 154 nM against CaMKIIδ.

Design, facile synthesis, antibacterial activity and structure-activity relationship of novel di- and tri-substituted 1,3,5-triazines

Due to overwhelming generation of drug resistant microorganisms, there is an urgent need to develop novel chemotherapeutic agents. In continuation of our research on discovery of novel heterocyclic scaffolds from 1,3,5-triazine, present study deals with design and development of some novel di- and tri-substituted 1,3,5-triazine derivatives. The synthesis of title analogues were accomplished by SNAr reaction and subsequently underwent rigorous antibacterial screening against a panel of representative Gram-negative and Gram-positive bacteria. Screening results revealed that minor structural variation may induce drastic changes in activity. Whereas, amine bridge and piprazine was termed as pivotal structural fragments necessary for generation and escalation of bio-activity. The structures of newly synthesized compounds were ascertained on the basis of their analytical and spectral profiles.